1. Introduction {#sec1-medicines-06-00109}
===============

For the past 20 years, extra-corporal membrane oxygenation (ECMO) use has remarkably increased, as it has become an essential rescue therapy for severe refractory cardiac and pulmonary dysfunction in both adults and children \[[@B1-medicines-06-00109]\]. In general, ECMO provides temporary support for patients who have a predicted mortality rate of 80% and above \[[@B2-medicines-06-00109]\]. Indications for ECMO can be categorized into: (1) Respiratory Support and (2) Cardiac Support. Based on the indication for ECMO, the modality of ECMO is adapted for the patient. Veno-venous (VV) ECMO provides only respiratory support, and requires patients to have stable hemodynamics, whereas veno-arterial (VA) ECMO provides dual cardiac and respiratory support \[[@B1-medicines-06-00109],[@B2-medicines-06-00109],[@B3-medicines-06-00109],[@B4-medicines-06-00109],[@B5-medicines-06-00109],[@B6-medicines-06-00109],[@B7-medicines-06-00109]\]. In VA ECMO, the blood bypasses both the heart and lungs. Generally, there is minimal vascular pulsatility in VA ECMO, while there is considerable pulsatility in VV ECMO. Pulsatility has been suggested to be essential in maintaining optimal perfusion to the vital organs, including the brain, heart and kidneys \[[@B8-medicines-06-00109]\]. For instance, Pappalardo et al. \[[@B9-medicines-06-00109]\] has shown that the incidence of acute ischemic stroke in VV ECMO is 1.4% compared to 3.8% in VA ECMO \[[@B10-medicines-06-00109]\].

A recent meta-analysis has demonstrated that the pooled incidence of AKI and severe AKI requiring renal replacement therapy (RRT) among adult patients on ECMO was 63% and 45%, respectively. Furthermore, adult ECMO patients with AKI requiring RRT have a significantly increased mortality with a pooled odds ratio (OR) of 3.73 \[[@B11-medicines-06-00109]\]. Although the incidence and associated mortality of AKI in adults on ECMO are widely reported, comparable data in the pediatric population are limited. While one study has reported a mortality rate of 27.4 and 41.6%, respectively, for neonatal and pediatric patients who received ECMO support for non-cardiac indications \[[@B12-medicines-06-00109]\], the impact of AKI and its severity on outcomes is less clear. Furthermore, the need for RRT during ECMO is considered an independent risk factor for the failure to wean from ECMO \[[@B13-medicines-06-00109]\]. Therefore, we performed this meta-analysis to assess the incidence rate of AKI and its associated mortality in pediatric patients receiving ECMO for various indications. The results of our study will help define the burden of AKI and its clinical impact on pediatric patients receiving ECMO, and allow comparisons to the adult counterpart.

2. Method {#sec2-medicines-06-00109}
=========

2.1. Literature Review and Search Strategy {#sec2dot1-medicines-06-00109}
------------------------------------------

We conducted a systematic literature review of Ovid MEDLINE, EMBASE and the Cochrane Database of Systematic Reviews until June 2019 to assess the incidence and mortality risk of AKI in pediatric patients on ECMO. Independent reviewers (C.T. and P.L.) conducted a systematic literature search using a search strategy that incorporated the search terms "extracorporeal membrane oxygenation" OR "ECMO" AND "acute kidney injury" OR "acute renal failure", as shown in [Supplementary Data S1](#app1-medicines-06-00109){ref-type="app"}. A manual search for potentially relevant studies utilizing the references of the initial included articles was subsequently performed. There was no language limitation. This systematic review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) \[[@B14-medicines-06-00109]\].

2.2. Selection Criteria {#sec2dot2-medicines-06-00109}
-----------------------

Inclusion criteria consisted of observational studies or clinical trials that evaluated both the incidence of acute kidney injury (AKI) and/or severe AKI requiring RRT and mortality risk of AKI in pediatric patients (aged younger than 18 years old) on ECMO. Retrieved articles were individually assessed for study eligibility by the two investigators previously noted. Any discrepancies were resolved by mutual consensus.

2.3. Data Abstraction {#sec2dot3-medicines-06-00109}
---------------------

A data collecting form was utilized to derive the following information from the individual studies: Title, study year, publication year, name of authors, country where the study was performed, ECMO type, definition of AKI, incidence rate of AKI, incidence rate of AKI requiring RRT and risk of mortality in pediatric patients on ECMO with AKI.

2.4. Statistical Analysis {#sec2dot4-medicines-06-00109}
-------------------------

Analyses were performed using the Comprehensive Meta-Analysis 3.3 software (version 3; Biostat Inc, Englewood, NJ, USA). Pooled AKI incidence and mortality risk of included studies were incorporated by the generic inverse variance method of DerSimonian-Laird, which indicated the weight of each study depending on its variance \[[@B15-medicines-06-00109]\]. Because of the likelihood of inter-observation variance, we utilized a random-effects model for meta-analyses of the incidence and mortality risk of AKI among pediatric patients receiving ECMO. Statistical heterogeneity of studies was evaluated by the Cochran's Q test (statistically significant as *p* \< 0.05) and the *I*^2^ statistic (≤25% represents insignificant heterogeneity, 26% to 50% represents low heterogeneity, 51% to 75% represents moderate heterogeneity, and ≥75% represents high heterogeneity) \[[@B16-medicines-06-00109]\]. Publication bias was evaluated via the Egger test \[[@B17-medicines-06-00109]\].

3. Results {#sec3-medicines-06-00109}
==========

Our search strategy produced a total of 1741 potentially eligible articles. 887 articles were excluded because they were duplicated. and 684 articles because they were case reports, correspondences, review articles, in vitro studies, or animal studies. 170 articles remained for full-length review. Forty one articles were subsequently excluded because the study cohort was an adult patient population, and 116 studies were excluded due to a lack of data on the outcomes of interest. Consequently, 13 cohort studies \[[@B12-medicines-06-00109],[@B18-medicines-06-00109],[@B19-medicines-06-00109],[@B20-medicines-06-00109],[@B21-medicines-06-00109],[@B22-medicines-06-00109],[@B23-medicines-06-00109],[@B24-medicines-06-00109],[@B25-medicines-06-00109],[@B26-medicines-06-00109],[@B27-medicines-06-00109],[@B28-medicines-06-00109],[@B29-medicines-06-00109]\] comprised of 3523 pediatric patients on ECMO were identified in this systematic review. The systematic review process is presented in [Figure 1](#medicines-06-00109-f001){ref-type="fig"}. The characteristics of the included studies are demonstrated in [Table 1](#medicines-06-00109-t001){ref-type="table"}. The kappa coefficient (0.87) indicated that agreement between the authors was acceptable.

3.1. Incidence of AKI among Pediatric Patients on ECMO {#sec3dot1-medicines-06-00109}
------------------------------------------------------

Pooled estimated incidence of AKI and severe AKI requiring RRT were 61.9% (95%CI: 39.0--80.4%, *I*^2^ = 98%, [Figure 2](#medicines-06-00109-f002){ref-type="fig"}A) and 40.9% (95%CI: 31.2--51.4%, *I*^2^ = 86%, [Figure 2](#medicines-06-00109-f002){ref-type="fig"}B), respectively. We additionally performed a meta-analysis limited to studies using standard AKI definitions; this showed a pooled estimated AKI incidence of 69.2% (95%CI: 59.7--77.3%, *I*^2^ = 83%, [Figure S1](#app1-medicines-06-00109){ref-type="app"}).

Subgroup analysis based on patient population (cardiac surgery vs. non-cardiac surgery) was performed. Pooled incidence of AKI was 81.4% (95%CI: 54.4--94.2%, *I*^2^ = 84%, [Figure S2](#app1-medicines-06-00109){ref-type="app"}) among patients after cardiac surgery and 52.3% (95%CI: 27.3--76.2%, *I*^2^ = 99%, [Figure S2](#app1-medicines-06-00109){ref-type="app"}) among non-cardiac surgery patients. Pooled incidence of AKI requiring RRT was 52.2% (95%CI: 32.5--71.2%, *I*^2^ = 88%, [Figure S3](#app1-medicines-06-00109){ref-type="app"}) among patients after cardiac surgery and 30.2% (95%CI: 18.7--44.9%, *I*^2^ = 84%, [Figure S3](#app1-medicines-06-00109){ref-type="app"}) among non-cardiac surgery patients.

3.2. Mortality in Pediatric ECMO Patients with AKI {#sec3dot2-medicines-06-00109}
--------------------------------------------------

[Table 1](#medicines-06-00109-t001){ref-type="table"} and [Table 2](#medicines-06-00109-t002){ref-type="table"} demonstrate the AKI-associated mortality rate and risk in pediatric patients on ECMO, respectively. Pooled estimated hospital or 90-day mortality rates of pediatric ECMO patients with AKI and AKI requiring RRT were 51.7% (95%CI: 26.5--76.0%, *I*^2^ = 96%, [Figure S4](#app1-medicines-06-00109){ref-type="app"}) and 61.8% (95%CI: 48.8--73.4%, *I*^2^ = 74%, [Figure S5](#app1-medicines-06-00109){ref-type="app"}), respectively.

The hospital mortality pooled OR in pediatric ECMO patients with AKI and severe AKI requiring RRT were 1.70 (95% CI: 1.38--2.10, *I*^2^ = 0%, [Figure 3](#medicines-06-00109-f003){ref-type="fig"}A) and 3.64 (95% CI, 2.02--6.55, *I*^2^ = 58%, [Figure 3](#medicines-06-00109-f003){ref-type="fig"}B), respectively. Meta-regression analysis was additionally performed, and it demonstrated that year of study was not correlated with either mortality risk associated with AKI (*p* = 0.65) or AKI requiring RRT (*p* = 0.46).

3.3. Assessment for Publication Bias {#sec3dot3-medicines-06-00109}
------------------------------------

Funnel plots ([Figures S6 and S7](#app1-medicines-06-00109){ref-type="app"}) and Egger's regression asymmetry tests were used to evaluate for publication bias. We found no significant publication bias for the incidence of AKI and severe AKI requiring RRT (*p* = 0.16 and *p* = 0.74, respectively).

4. Discussion {#sec4-medicines-06-00109}
=============

In this study, we have shown that the incidence of AKI and severe AKI in the pediatric population requiring ECMO is high (62% and 41%, respectively), especially in cardiac surgery patients requiring ECMO. AKI is associated with high mortality (OR 3.64) and AKI-associated mortality did not change over time. Similar to the adult population, our study in pediatric patients concurs that ECMO is associated with a higher risk of AKI and hospital mortality \[[@B11-medicines-06-00109]\].

The mechanism by which ECMO support predisposes patients to AKI is not well established. Certainly, patients requiring ECMO often possess many known comorbidities and risk factors for AKI, such as low cardiac output, septic shock, anemia, diabetes, exposure to nephrotoxic drugs, etc. \[[@B30-medicines-06-00109],[@B31-medicines-06-00109]\]. In general, there are fewer comorbidities among pediatric patients. Conversely, their renal reserve may not have fully developed \[[@B12-medicines-06-00109]\].

However, it is proposed that ECMO itself is capable of inducing AKI via detrimental (1) hemodynamic alterations; (2) hormonal imbalances; and (3) systemic inflammatory cytokines \[[@B11-medicines-06-00109],[@B30-medicines-06-00109],[@B31-medicines-06-00109]\]. Hemodynamic alterations may include the potential loss of pulsatility with VA ECMO versus the maintenance of pulsatility with VV ECMO. Evidence is supportive of the vital impact of pulsatility on maintaining renal cortical perfusion, thus helping to prevent acute tubular necrosis \[[@B8-medicines-06-00109]\]. Slight hemodynamic changes could potentiate a significant reduction in renal perfusion. Current data on ECMO-associated hormonal changes show conflicting evidence. Saito et al. hypothesized that upregulation of plasma renin activity may be an adaptive response to the loss of pulsatile renal perfusion \[[@B32-medicines-06-00109]\]. However, Semmekrot et al. observed a reduction of atrial natriuretic peptide (ANP) level, plasma renin activity (PRA) and angiotensin II levels in neonates requiring VA ECMO \[[@B33-medicines-06-00109]\]. Further clinical investigation is needed to better understand the impact and interaction of different hormones on renal perfusion. Finally, studies have demonstrated that the continuous exposure of blood to the non-endothelialized/non-biological ECMO interface results in an activation of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), IL (interleukin)-1β, IL-6, IL-8 \[[@B34-medicines-06-00109],[@B35-medicines-06-00109]\].

Our study shows that the incidence of AKI, severe AKI requiring RRT and AKI-associated hospital mortality between adults and pediatric patients are similar \[[@B11-medicines-06-00109]\]. This further supports ECMO as a potential independent predictor for AKI. However, we found a significant higher incidence of AKI and RRT in pediatric patients that the indication for ECMO was after cardiac surgery, than those who required ECMO for non-cardiac surgery related conditions. Despite improved knowledge of the indications for ECMO, patient comorbidities, and associated risk factors that may contribute to ECMO-associated AKI, ECMO as an independent risk factor for AKI cannot be determined from this meta-analysis alone. A pooled meta-analysis of both adult and pediatric patients assessing the incidence of AKI and mortality following ECMO support would be useful. Furthermore, a subgroup analysis comparing adult and pediatric patients would further elaborate whether ECMO is associated with AKI and increased mortality.

There were a few limitations in this study. Most of the included studies defined AKI based on serum creatinine levels, while studies utilizing the more sensitive urine output criteria or use of novel AKI biomarkers were limited \[[@B36-medicines-06-00109]\]. Moreover, our meta-analysis is primarily based on observational studies, making it impossible to establish a causal relationship. Future data from population-based studies or prospective clinical trials focusing on AKI prevention in ECMO patients would be beneficial.

5. Conclusions {#sec5-medicines-06-00109}
==============

Our study demonstrates that AKI is common following ECMO in pediatric patients with an incidence of 68%. Approximately 40% of pediatric patients on ECMO develop severe AKI requiring RRT. We have also shown that presence of AKI is associated with a higher risk of hospital mortality. There is no difference in mortality between recent and remote studies. Clinical trials focusing on preventive measures for AKI with ECMO therapy is also encouraged.

The following are available online at <https://www.mdpi.com/2305-6320/6/4/109/s1>, Data S1: Search terms for systematic review, Figure S1: Forest plots of the included studies assessing incidence of AKI limited to studies with standard AKI definitions was performed and demonstrated the pooled estimated incidence of AKI, Figure S2: Forest plots of the included studies assessing incidence of AKI based on cardiac surgery status, Figure S3: Forest plots of the included studies assessing incidence of severe AKI requiring RRT based on cardiac surgery status, Figure S4: Forest plots of the included studies assessing hospital and/or 90-day mortality rates of pediatric patients on ECMO with AKI, Figure S5: Forest plots of the included studies assessing hospital and/or 90-day mortality rates of pediatric patients on ECMO with severe AKI requiring RRT, Figure S6: Funnel plot evaluating for publication bias evaluating incidence of AKI while on ECMO, Figure S7: Funnel plot evaluating for publication bias evaluating incidence of severe AKI requiring RRT while on ECMO.

###### 

Click here for additional data file.
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medicines-06-00109-t001_Table 1

###### 

Included studies in this systematic review of acute kidney injury (AKI) incidence and mortality in pediatric patients requiring ECMO.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                             Year   Country        Patient Population                                                                               Number      Definition of AKI                                                       Incidence of AKI                                     Mortality
  ------------------------------------------------- ------ -------------- ------------------------------------------------------------------------------------------------ ----------- ----------------------------------------------------------------------- ---------------------------------------------------- ----------------------------------
  Kolovos et al. \[[@B18-medicines-06-00109]\]      2003   USA            Patients on ECMO within seven days after cardiac surgery                                         74          RRT                                                                     RRT 26/74 (35%)\                                     Hospital mortality\
                                                                                                                                                                                                                                                                                                                    RRT 20/26 (77%)

  Hoover et al. \[[@B19-medicines-06-00109]\]       2008   USA            Patients aged 1 month to 18 years with respiratory failure requiring ECMO                        86          CRRT                                                                    CRRT 26/86 (30%)                                     Hospital mortality\
                                                                                                                                                                                                                                                                                                                    RRT 7/26 (27%)

  Gbadegesin et al. \[[@B20-medicines-06-00109]\]   2009   USA            Patients aged \< 3 years requiring ECMO after cardiac surgery                                    104         CRRT                                                                    CRRT 42/104 (40%)                                    Hospital mortality\
                                                                                                                                                                                                                                                                                                                    RRT 35/42 (83%)

  Gadepalli et al. \[[@B21-medicines-06-00109]\]    2010   USA            Congenital diaphragmatic hernia patients requiring ECMO\                                         68          AKI: RIFLE                                                              AKI\                                                 Mortality\
                                                                                                                                                                                                                                                               48/68 (71%)\                                         RIFLE---failure AKI 24/33 (73%)\
                                                                                                                                                                                                                                                               RIFLE---failure AKI\                                 
                                                                                                                                                                                                                                                               33/68 (49%)\                                         
                                                                                                                                                                                                                                                               CRRT\                                                
                                                                                                                                                                                                                                                               11/68 = 16%                                          

  Goto et al. \[[@B22-medicines-06-00109]\]         2011   USA            Patients aged 19 days to 20 years with respiratory failure and/or heart failure requiring ECMO   14          RRT                                                                     RRT 7/14 (50%)                                       Hospital mortality\
                                                                                                                                                                                                                                                                                                                    RRT 2/7 (29%)

  Askenazi et al. \[[@B12-medicines-06-00109]\]     2011   USA            All non-cardiac patients requiring ECMO                                                          9903\       SCr \> 1.5 mg/dL or ICD-9 for acute renal failure                       Neonates\                                            Neonates\
                                                                                                                                                                           Neonates\                                                                           AKI---638/7941 (8%)\                                 Hospital mortality\
                                                                                                                                                                           -7941\                                                                              RRT---1786/7941 (22%)\                               AKI---413/638 (65%)\
                                                                                                                                                                           Children\                                                                           Children\                                            RRT---863/1786 (48%)\
                                                                                                                                                                           -1962\                                                                              AKI---402/1962 (20%)\                                Children\
                                                                                                                                                                                                                                                               RRT---840/1962 (43%)                                 Hospital mortality\
                                                                                                                                                                                                                                                                                                                    AKI---264/402 (66%)\
                                                                                                                                                                                                                                                                                                                    RRT---487/840 (58%)

  Ricci et al. \[[@B23-medicines-06-00109]\]        2012   Italy          Patients aged 13 days to 13 years on VA ECMO after cardiac surgery                               10          CRRT                                                                    CRRT 3/10 (30%)                                      Hospital mortality\
                                                                                                                                                                                                                                                                                                                    RRT 2/3 (66%)\

  Hoffman et al. \[[@B24-medicines-06-00109]\]      2013   USA            Patients with persistent hypoxia or cardiovascular instability requiring ECMO                    10          AKI; (1) urine output \< 1 ml/kg/h with SCr \> 1 mg/dL for 24 hours,\   AKI 5/10 (50%)\                                      N/A
                                                                                                                                                                                       (2) SCr of \> 1.5 mg/dL,\                                                                                                    
                                                                                                                                                                                       (3) failure to improve creatinine clearance by \> 50%                                                                        

  Zwiers et al. \[[@B25-medicines-06-00109]\]       2013   Netherlands    Neonates aged \< 28 days requiring ECMO                                                          242         AKI: RIFLE                                                              AKI\                                                 Hospital mortality\
                                                                                                                                                                                                                                                               153/242 (63%)                                        AKI 43/153 (28%)

  Fleming et al. \[[@B26-medicines-06-00109]\]      2016   USA            Pediatric patients aged \< 18 requiring ECMO                                                     832         AKI: KDIGO                                                              AKI by SCr---502/832 (60%)\                          N/A
                                                                                                                                                                                                                                                               AKI by SCr + renal support therapy---615/832 (74%)   

  Yang et al. \[[@B27-medicines-06-00109]\]         2016   China          Patients aged 1 to 13 years with refractory cardiopulmonary failure requiring ECMO               12          CRRT                                                                    CRRT 1/12 (8%)                                       Hospital mortality\
                                                                                                                                                                                                                                                                                                                    RRT 0/1 (0%)

  Elella et al. \[[@B28-medicines-06-00109]\]       2017   Saudi Arabia   Pediatric patients requiring VA-ECMO after cardiac surgery                                       59          AKI pRIFLE                                                              AKI\                                                 Hospital mortality\
                                                                                                                                                                                                                                                               53/59 (90%)\                                         AKI 33/53 (62%)\
                                                                                                                                                                                                                                                               RRT\                                                 
                                                                                                                                                                                                                                                               29/59 (49%)                                          

  Borasino et al. \[[@B29-medicines-06-00109]\]     2018   USA            Pediatric cardiac patient on ECMO in CICU                                                        50          AKI: increase in SCr of 200% from baseline                              AKI\                                                 Hospital mortality\
                                                                                                                                                                                                                                                               35/50 (70%)\                                         RRT 16/26 (61%)
                                                                                                                                                                                                                                                               RRT\                                                 
                                                                                                                                                                                                                                                               26/50 (52%)                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKIN, Acute Kidney Injury Network; COPD, chronic obstructive pulmonary disease; CRRT, continuous renal replacement therapy; KDIGO, Kidney Disease Improving Global Outcomes; pRIFLE, Pediatric Risk, Injury, Failure, Loss of kidney function; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; RRT, renal replacement therapy; SCr, serum creatinine; ECMO, extra-corporal membrane oxygenation.

medicines-06-00109-t002_Table 2

###### 

Mortality Risk of AKI among pediatric patients requiring ECMO.

  -------------------------------------------------------------------------------------------------------------------------------
  Study                                             Mortality Rate                     OR for Mortality
  ------------------------------------------------- ---------------------------------- ------------------------------------------
  Kolovos et al. \[[@B18-medicines-06-00109]\]      Hospital mortality\                Hospital mortality\
                                                    RRT 20/26 (77%)                    RRT: OR 5.6 (1.8--17.9)

  Hoover et al. \[[@B19-medicines-06-00109]\]       Hospital mortality\                Hospital mortality\
                                                    RRT 7/26 (27%)                     CRRT: 1.55 (0.42--5.70)

  Gbadegesin et al. \[[@B20-medicines-06-00109]\]   Hospital mortality\                Hospital mortality\
                                                    RRT 35/42 (83%)                    CRRT: 9.8 (3.7--25.7)

  Gadepalli et al. \[[@B21-medicines-06-00109]\]    Mortality\                         Hospital mortality\
                                                    RIFLE---failure AKI 24/33 (73%)\   RIFLE---Failure AKI: 10.67 (3.45--32.96)

  Goto et al. \[[@B22-medicines-06-00109]\]         Hospital mortality\                Hospital mortality\
                                                    RRT 2/7 (29%)                      RRT: 0.53 (0.06--4.91)

  Askenazi et al. \[[@B12-medicines-06-00109]\]     Neonates\                          Hospital mortality\
                                                    Hospital mortality\                Neonates\
                                                    AKI---413/638 (65%)\               AKI: 3.2 (2.6--4.0)\
                                                    RRT---863/1786 (48%)\              RRT: 1.9 (1.6--2.2)\
                                                    Children\                          Children\
                                                    Hospital mortality\                AKI: 1.7 (1.3--2.3)\
                                                    AKI---264/402 (66%)\               RRT: 2.5 (1.9--3.2)
                                                    RRT---487/840 (58%)                

  Ricci et al. \[[@B23-medicines-06-00109]\]        Hospital mortality\                Hospital mortality\
                                                    RRT 2/3 (66%)                      CRRT: 2.67 (0.16--45.14)

  Zwiers et al. \[[@B25-medicines-06-00109]\]       Hospital mortality\                Hospital mortality\
                                                    AKI 43/153 (28%)                   AKI: 1.35 (0.73--2.48)

  Fleming et al. \[[@B26-medicines-06-00109]\]      N/A                                Hospital mortality\
                                                                                       AKI-SCr: 1.77 (1.22--2.55)\
                                                                                       AKI-SCr+RST: 2.50 (1.61--3.90)

  Yang et al. \[[@B27-medicines-06-00109]\]         Hospital mortality\                Hospital mortality\
                                                    RRT 0/1 (0%)                       CRRT: 0/1 vs. 4/11

  Elella et al. \[[@B28-medicines-06-00109]\]       Hospital mortality\                Hospital mortality\
                                                    AKI 33/53 (62%)                    AKI: 8.25 (0.90--75.79)

  Borasino et al. \[[@B29-medicines-06-00109]\]     Hospital mortality\                Hospital morality\
                                                    RRT 16/26 (61%)                    RRT: 2.67 (0.85--8.37)
  -------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AKIN, Acute Kidney Injury Network; COPD, chronic obstructive pulmonary disease; CRRT, continuous renal replacement therapy; KDIGO, Kidney Disease Improving Global Outcomes; pRIFLE, Pediatric Risk, Injury, Failure, Loss of kidney function; RIFLE, Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease; RRT, renal replacement therapy; RST, renal support therapy; SCr, serum creatinine.
